medigraphic.com
Coordinación General de Investigación de la Facultad de Salud Pública y Nutrición y la Dirección General de Sistemas e Informática de la Universidad Autónoma de Nuevo León

2004, Number 4

<< Back

Rev Salud Publica Nutr 2004; 5 (4)

El tropismo del VIH y su fenotipificación.

Lara VHH, Ixtepan TLC, Rodríguez PC

Language: Spanish
References: 31
Page:
PDF size: 187.91 Kb.


ABSTRACT

The research focus in the BSL-3 begins with obtaining an understanding of the specific interactions between HIV viral components and human proteins. This process will define which host factors are required for a productive infection. An immediate objective of these studies is to provide new targets for the development of novel drug therapies. Using what is learned from these molecular studies, they are attempting to develop small animal models to study the interaction of HIV with the host’s immune system.


REFERENCES

  1. Barre-Sinoussi F, JC. Chermann ,F. Rey ,MT. Nugeyre ,S. Chamaret ,J. Gruest ,C. Dauguet ,C. Axler- Blin ,F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum and L. Montagnier 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science;220(4599):868- 871

  2. Gallo, RC, PS. Sarin, EP. Gelmann, M. Robert-Guroff, E. Richardson, VS. Kalyanaraman, D. Mann, GD. Sidhu, RE. Stahl, S. Zolla-Pazner, J. Leibowitch and M. Popovic. 1983 Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science;220(4599):865-867

  3. Alkhatib G, CC. Broder and EA. Berger. 1996a. Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J Virol. 70(8):5487- 5494

  4. Alkhatib G, C. Combadiere, CC. Broder, Y. Feng, PE. Kennedy, PM. Murphy and EA. Berger. 1996b. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science;272(5270):1955-1958.

  5. Trkola A, T. Dragic, J. Arthos, JM. Binley, WC. Olson, GP. Allaway, C. Cheng-Mayer, J. Robinson, PJ. Maddon, and JP. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature;384(6605):184-187.

  6. Wu L, NP. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, AA. Cardoso, E. Desjardin, W. Newman, C. Gerard and J. Sodroski.1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature.;384(6605):179-183.

  7. Koot M., A.H.V. Vos, R.P.M. Keet,R.E.Y. de Goede, W. Dercksen, F.G. Terpstra, R.A. Coutinho, F. Miedema, and M. Tersmette 1992 HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 6:49–54.

  8. Asjo B., L. Morfeldt-Manson, J. Albert, G. Biberfeld, A. Karlsson, K. Lidman, and EM. Fenyo 1986 .Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. ii:660–662.

  9. Fenyo, E.M, L. Morfeldt-Manson, F. Chiodi, A. Lind, A. von Gegerfelt, J. Albert, E. Olausson, and B. Asjo, 1988. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol. 62:4414–4419.

  10. Tersmette M., R E. de Goede, B.J. Al, I.N. Winkel, R.A. Gruters, H.T. Cuypers, H.G. Huisman, and F. Miedema 1988 Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol, 62:2026–2032.

  11. Alkhatib G,C.et al, Op. cit. 1996a

  12. Alkhatib G,C.et al, Op. cit 1996b

  13. Trkola A. et al, Op. cit

  14. Wu L, et al, Op. cit

  15. Furci L, G. Scarlatti and S. Burastero.1997. Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med; 186: 455-460.

  16. Trkola A, T. Dragic, and J. Arthos. 1996. CD4-dependent, antibody-sentive interactions between HIV-1 and its co-receptor CCR-5- Nature; 384 (6605): 814-817

  17. Balfe P, Y. Churcher and M. Penny 1998. Association between a defective CCR-5 gene and progression to disease in HIV infection. AIDS Res Hum Retroviruses; 14: 1229-1234.

  18. Gorry PR, C. Zhang, S. Wu, K. Kunstman, E. Trachtenberg, J. Phair, S. Wolinsky and D. Gabuzda. 2002 Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet. May 25;359(9320):1832-1834.

  19. Moriuchi H, M. Moriuchi, C. Combadiere, PM. Murphy and AS. 1996 Fauci.CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages Proc Natl Acad Sci U S A.;93(26):15341-15345.

  20. Ahmed RK, B. Makitalo, K. Karlen, C. Nilsson, G. Biberfeld and R. Thorstensson. 2002 Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge. Clin Exp Immunol;129(1):11-18.

  21. Trujillo JR, WK. Wang, TH. Lee and M. Essex. 1996 Identification of the envelope V3 loop as a determinant of a CD4-negative neuronal cell tropism for HIV-1. Virology.;217(2):613-617.

  22. Doranz BJ., K. Grovit-Ferbas, MP. Sharron, SH. Mao, MB. Goetz, ES. Daar , RW. Doms and WA. O'Brien.1997 A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med.;186(8):1395-1400

  23. Tamamura H, T. Murakami, M. Masuda, A. Otaka, W. Takada, T. Ibuka, H. Nakashima, M. Waki, A. Matsumoto and N. Yamamoto. 1994. Structure-activity relationships of an anti-HIV peptide, T22. Biochem Biophys Res Commun.;205(3):1729-1735.

  24. De Clercq E and D. Schols 2001.Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists. Antivir Chem Chemother.;12 Suppl 1:19-31

  25. Daelemans D, D. Schols, M. Witvrouw, C. Pannecouque, S. Hatse, S. van Dooren, F. Hamy, T. Klimkait, E. de Clercq and AM.VanDamme .2000 A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol. 57(1):116-124.

  26. Armand-Ugon M, ME. Quinones-Mateu , A. Gutierez, J. Barretina, J. Blanco, D. Schols, E. De Clercq, B. Clotet, JA. Este. 2003 Reduced fitness of HIV-1 resistant to CXCR4 antagonists. Antivir Ther;8(1):1-8.

  27. De Clercq E. 2002 New developments in anti-HIV chemotherapy Biochim Biophys Acta.;1587(2- 3):258-275.

  28. Litovchick A, A. Lapidot, M. Eisenstein, A. Kalinkovich and G. Borkow. 2001 Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry.;40(51):15612- 15623.

  29. Lapidot A., M. Eisenstein, A. Kalinkovich and G. Borkow, 2002 Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities, Antivir. Res. 53 (3): 26 Sp. Iss.

  30. Borkow G., V. Vijayabaskar , HH. Lara, A. Kalinkovich and A. Lapidot,2003.Structure-activity relationship of neomycin, paromomycin and neamine- arginine conjugates, targeting HIV-1 gp120-CXCR4 binding step. Antiviral Res.;60(3):181-192.

  31. Borkow G, HH. Lara and A. Lapidot . 2003. Mutations in gp41 and gp120 of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate. Biochem Biophys Res Commun.;312(4):1047-1052.




2020     |     www.medigraphic.com